Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03939481 · ClinicalTrials.gov registry record
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
A clinical trial of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, sponsored by SWOG Cancer Research Network.
- Active
- Registry status
- 1,336
- Enrollment target
- 20
- Study locations
NCT03939481: Active study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, sponsored by SWOG Cancer Research Network.
NCT03939481 is a study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8 that is active but no longer recruiting, run by SWOG Cancer Research Network. The registered enrollment target is 1,336 participants, above the 289-participant average among 84 other Anatomic Stage III Breast Cancer AJCC v8 trials with a reported enrollment target (362% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03939481, a study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, is active but no longer recruiting, sponsored by SWOG Cancer Research Network.
- ACTIVE NOT RECRUITING
- Registry status
- 1,336 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can lead to tingling or less feeling in hands and feet. Studying certain risk factors, such as age, gender, pre-existing conditions, and the type of treatment for cancer may help doctors estimate how likely patients are to develop the nerve disorder.
Primary Outcome
Will be measured as an absolute increase of \>= 8 points over the baseline chemotherapy-induced peripheral neuropathy (CIPN)-20 sensory neuropathy subscale score. Will be collected before or at the 24-week assessment..
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- OTHER Functional Assessment
- DRUG Chemotherapy
Study Locations (20)
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Kaiser Permanente Dublin - Dublin
- Kaiser Permanente-Fremont - Fremont
- Kaiser Permanente-Fresno - Fresno
- Kaiser Permanente-Oakland - Oakland
- Desert Regional Medical Center - Palm Springs
- Kaiser Permanente-San Francisco - San Francisco
- Kaiser Permanente-Santa Teresa-San Jose - San Jose
- Kaiser Permanente San Leandro - San Leandro
- Kaiser San Rafael-Gallinas - San Rafael
- Kaiser Permanente Medical Center - Santa Clara - Santa Clara
- Kaiser Permanente-Santa Rosa - Santa Rosa
- Kaiser Permanente Medical Center-Vacaville - Vacaville
- Kaiser Permanente-Vallejo - Vallejo
- Kaiser Permanente-Walnut Creek - Walnut Creek
Delaware
- Bayhealth Hospital Kent Campus - Dover
- Bayhealth Hospital Sussex Campus - Milford
Florida
- Florida Gynecologic Oncology - Fort Myers
- Regional Cancer Center-Lee Memorial Health System - Fort Myers
Colorado
- Rocky Mountain Regional VA Medical Center - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,336 participants |
| Start Date | 2019-05-14 |
| Est. Completion | 2026-02-28 |
What the registry record for NCT03939481 still lists
NCT03939481 is an observational study that tracks outcomes without assigning an intervention. Its 1,336 participants enrollment target places it among the larger protocols in the corpus, above the 289-participant average among 84 other Anatomic Stage III Breast Cancer AJCC v8 trials with a reported enrollment target (362% higher).
The record links to 10 conditions, with Anatomic Stage III Breast Cancer AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT03939481 names 20 study sites across 4 states, led by California, Delaware, Florida.
Frequently Asked Questions
What is clinical trial NCT03939481 about?
NCT03939481 is a clinical study titled "Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer". This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can lead to tingling or less feeling in hands and feet. Studying certain risk...
What is the current status of trial NCT03939481?
This trial is currently active not recruiting. The enrollment target is 1,336 participants. The study started on 2019-05-14. Estimated completion is 2026-02-28.
What conditions does trial NCT03939481 study?
This clinical trial studies the following conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8.
What interventions are being tested in trial NCT03939481?
The interventions under investigation include: Questionnaire Administration (OTHER), Functional Assessment (OTHER), Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03939481?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03939481 being conducted?
This trial has 20 study locations across California, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anatomic Stage III Breast Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03939481's enrollment target sits among peer trials
1,336 5th of 84 higher than 80 of 84 other Anatomic Stage III Breast Cancer AJCC v8 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anatomic Stage III Breast Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment
RECRUITING · NA
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
RECRUITING · NA
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06972056 · 1,335 participants · Phase 4
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- NCT05415761 · 1,332 participants · NA
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
- NCT05511298 · 1,332 participants
Empowering Students Project
- NCT06934876 · 1,332 participants
Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI